Presentation to Include Additional Details on Phase III Trial Design of Multikine
CEL-SCI Corporation (NYSE AMEX: CVM) announced today that Eyal Talor, Ph.D., its Chief Scientific Officer, will deliver a presentation titled "LEAPS Peptides and Protein Vaccines and Multikine® Immunotherapy for Cancer" on April 14th at the World Vaccine Congress 2011 at 2:50 p.m. at the Gaylord National Hotel and Convention Center, Washington DC. The Conference brings together North America's leading governmental, business and scientific leaders as they continue to enhance the scientific and strategic innovation behind the emerging vaccine industry.
Dr. Talor will discuss the next generation of cancer vaccines, including Multikine Immunotherapy, which offer a new approach to vaccine design and which may be able to overcome some of the difficulties encountered by the currently used and more traditional cancer vaccines. This new approach to the design and development of cancer vaccines and treatment does not rely on the need for isolating autologous (the patient's own) tumor antigens for the production of these vaccines and treatments, and may also be able to withstand tumor mutations and overcome tumor mechanisms that are directed towards the inhibition of an effective anti-tumor response, in cancer patients.
Dr. Talor's discussion also includes a summary of Multikine's results in Phase I/II and provides details on the design of the Phase III study currently underway. The presentation also discusses LEAPS as a peptide technology that is being developed as a Platform Technology for Vaccines, including applications in areas of Rheumatoid Arthritis, HSV, H1N1 and Cancer vaccines. In addition, Dr. Talor provides an update on the work that the Company is doing in developing dendritic vaccines for other emerging viral diseases.
About CEL-SCI Corporation
CEL-SCI Corporation is developing products that empower immune defenses. Its lead product, Multikine is currently being tested in a global Phase III clinical trial that started in December 2010. In Phase II clinical trials Multikine was shown to be safe and well-tolerated and to improve the patients overall survival by 33 percent at a median of three and half years following surgery.
CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its LEAPS technology platform. The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2010. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contacts:
CEL-SCI Corporation
Gavin de Windt, 703-506-9460